NCT06095934

Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

Exploration of the Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Combined With Neoantigen Peptide Vaccine and Chemotherapy in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy (ORR) and safety of anti PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy in the treatment of advanced NSCLC progressed after EGFR-TKI treatment and to provide new treatment methods for EGFR-TKI resistant patients.

Conditions

• NSCLC
• EGFR Gene Mutation

Interventions

Type	Name	Description
OTHER	neo-antigen vaccine	anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy

Timeline

• Start date: 2022-03-01
• Primary completion: 2024-04-30
• Completion: 2025-12-30
• First posted: 2023-10-23
• Last updated: 2023-10-23

Locations

1 site across 1 country: China